药剂师服务价值支付的设计:一个范围审查
Sinaa A Al-Aqeel1, Shiekha S AlAujan1, Manar Alowaisi1
1Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Research in social & administrative pharmacy : RSAP
|March 3, 2026
概括
药剂师服务的基于价值的支付 (VBP) 模式正在出现,但面临实施挑战. 解决基础设施,文档和提供者的认可是成功扩展这些创新的医疗保健支付策略的关键.
科学领域:
- 医疗保健服务研究 医疗服务研究
- 药房实践 在药房实践.
- 卫生经济学 卫生经济学
背景情况:
- 基于价值的支付 (VBP) 模式越来越多地被探索,以激励医疗保健提供者.
- 药剂师在各种环境中提供基本的非处方服务,但它们与VBP模型的整合需要进一步调查.
研究的目的:
- 进行范围审查,总结有关实施药剂师提供的非处方服务的VBP模型的已发表研究.
- 确定在医院和社区药房设置中遇到的共同VBP模型,支付机制和障碍.
主要方法:
- 在PubMed,Web of Science和ProQuest进行了全面的文献搜索,搜索了2005年至2025年3月间发表的研究.
- 描述或评估药剂师服务的VBP的研究被选,由至少两位作者选择,并使用叙事合成进行分析.
主要成果:
- 包括17项研究,重点关注VBP模型实施,提案和利益相关者的看法.
- 常见的VBP方法包括按绩效支付和捆绑支付,分层或绝对激励结构.
- 确定的主要障碍是时间限制,文档/账单复杂性,数据基础设施不足以及药剂师缺乏正式的供应商认可.
结论:
- 药剂师主导的VBP模型显示出希望,但面临着阻碍复制的重大透明度问题.
- 克服实施障碍,包括基础设施发展和正式提供者地位,对于扩大药房实践中的VBP至关重要.
更多相关视频
相关概念视频
Issues And Trends In Healthcare Delivery System
6.5K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.5K
Health Information Technology and Healthcare Information System
1.7K
Health Information Technology (HIT)
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
Health Information Technology, commonly called HIT, integrates advanced information systems and technology in healthcare settings. Its primary functions include:
1.7K
Biopharmaceutics and Pharmacokinetics: Overview
4.7K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.7K
Biopharmaceutical Factors Influencing Drug Product Design: Overview
561
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
561
Dosage Regimens: Designs and Approaches
605
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
605
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


